Hair Health Essentials · Research Programme
Strand 02Menopause & Hair
Characterising hair change across the menopausal transition
Hair change is among the concerns women raise most consistently through perimenopause and beyond — and among the least clinically addressed. This strand establishes a structured framework for characterising it across the whole transition: from the fluctuating oestrogen of perimenopause to the sustained withdrawal that follows, in specialist trichological practice.
Phase 1 · Assessment framework established · Longitudinal documentation underway
01 · The Concern
Common to raise. Rarely addressed.
Hair change is one of the concerns women raise most often through the menopausal transition, and one of the least often met with a clinical framework of its own. It is frequently dismissed as ageing, folded into a general list of symptoms, or addressed without reference to the endocrinology driving it.
The transition is not a single event. Perimenopause brings fluctuating oestrogen and diffuse, unpredictable shedding. The postmenopausal state brings sustained oestrogen withdrawal and, with it, the progressive miniaturisation of female pattern hair loss. These are different presentations, with different courses — and they are routinely treated as one.
Distinguishing them, and documenting the full clinical picture around each, is the work this strand undertakes.
The transition unfolds over years, not weeks. A study of the hair should do the same.
02 · The Framework
Eight dimensions, recorded for every case
The assessment protocol applied across this strand. Each dimension is documented to a consistent standard, producing a structured record rather than a clinical impression.
01
Endocrine Staging
Position within the transition — perimenopausal fluctuation or postmenopausal steady state — and the shifting oestrogen-to-androgen balance that drives follicular change. Contraceptive and HRT history recorded here.
02
Trichoscopic Pattern
Follicular assessment under magnification, distinguishing diffuse telogen shedding from the patterned miniaturisation of female pattern hair loss the transition frequently unmasks. The central clinical distinction.
03
Thyroid & Haematology
Thyroid dysfunction peaks at this stage of life and both mimics and compounds menopausal shedding. Ferritin, full blood count and thyroid function interpreted against thresholds relevant to the follicle.
04
Nutritional Status
Dietary and metabolic shifts across midlife — protein adequacy, micronutrient status, changes in appetite and absorption — assessed for their contribution to follicular supply.
05
Psychological & Identity Context
Hair change at this stage carries disproportionate emotional weight, bound to identity, visibility and ageing. Distress, coping and impact captured structurally rather than anecdotally.
06
Systemic Load
Vasomotor symptoms, sleep disruption and the associated stress response — the whole-body burden of the transition, and its downstream effect on the growth cycle.
07
Scalp Environment
Oestrogen withdrawal alters sebum, barrier function and cutaneous ageing. The scalp is assessed as the environment in which regrowth must occur, independent of the shedding itself.
08
Longitudinal Course
Change tracked across the transition rather than captured at a single visit — the defining feature of this strand’s design, and of the phenomenon it studies.
03 · Clinical Understanding
What the endocrinology establishes
Oestrogen extends the active growth phase of the hair cycle. As it declines through the transition, that phase shortens: more follicles enter the shedding phase together, and diffuse thinning follows — the pattern most typical of perimenopause.
As oestrogen settles at a sustained low, the relative influence of androgens rises, even where absolute androgen levels remain normal. In genetically susceptible women this drives the progressive follicular miniaturisation of female pattern hair loss — the pattern more typical of the postmenopausal years.
Around both sit factors that peak at precisely this stage of life: thyroid dysfunction, shifting iron and nutritional status, sleep disruption and psychological stress. Any can initiate or deepen shedding; several often act together. Isolating their contribution is a clinical task, not a laboratory one.
Reflects established endocrine and dermatological understanding of hair across the menopausal transition. Specific references are compiled in the study documentation. This strand documents how the picture presents in individual clinical practice.
04 · The Approach
Characterisation over a lifetime, not a window
Most studies observe a moment — a trial window of weeks, a single assessment, a cohort measured once. Hair through the menopausal transition does not fit that shape. This strand is built to follow it.
The transition is the unit of study
Perimenopause to postmenopause is a passage of years. This strand follows women across it, rather than sampling them at a single point within it.
Continuous, not concluded
Documentation is accretive. The record deepens over time rather than closing at a fixed endpoint — matching a phenomenon that itself unfolds slowly.
Lived alongside the clinic
Because this work sits within ongoing clinical care, the same women can be characterised repeatedly across years — a vantage short studies cannot reach.
It is a slower way to study hair. It is also the way hair actually changes.
05 · Programme Phase
Where this strand stands
Phase 1
Current
Framework & documentation
The assessment framework is established and in application. Women are being characterised across the transition as part of ongoing clinical care.
Phase 2
Ongoing
Longitudinal accrual
The record deepens as the same patients are re-assessed across the peri-to-post arc — the continuous core of the strand.
Phase 3
Planned
Analysis & peer review
Structured analysis and submission for peer review, with documentation continuing beyond it. No findings disseminated before peer review.
06 · Research Standards
The standards this programme holds to
Findings are not disseminated before peer review
No result, pattern, proportion or outcome from this strand will be published, promoted or implied prior to completion of peer review. Programme phase and methodology are communicated; findings are not.
Descriptive by design
This strand characterises a clinical presentation and its course. It is not constructed to establish causation, and no causal claim is made or will be made from it.
No efficacy claim attaches to this work
The programme characterises presentation and course. It is not designed to evaluate the effectiveness of any treatment, including hormone replacement therapy, and makes no such claim.
Consistency of clinical observation
All clinical assessment within this strand is conducted by a single trichologist applying one method, eliminating inter-observer variability. Assessments are correspondingly not independently verified. Both conditions are stated.
Separation of observation and analysis
Clinical assessment and methodological handling — study design, data structure, anonymisation and reporting — are held separately within the team, as a deliberate safeguard against interpretive bias in practice-based research.
Interests declared in full
This programme is conducted within a commercial trichology practice. The practice and the team hold a commercial interest in trichology services relevant to the population documented. This is declared here and in any submitted manuscript. No external or pharmaceutical funding has been received.
07 · Programme
Active research strands
Strand 01
GLP-1 & Hair Shedding
Phase 1 · Active
Characterising hair shedding concurrent with GLP-1 receptor agonist therapy across eight clinical dimensions.
Strand 02
Menopause & Hair
Phase 1 · Active
Characterising hair change across the perimenopausal and postmenopausal transition through a continuous, longitudinal framework.
Clinical lead: Clare Devereux, IAT Certified Trichologist. Harley Street, London. Clinics also in Dublin.
This page describes research in progress and is provided for information only. It does not constitute medical advice. Anyone with concerns about hair change through menopause should seek individual clinical assessment.
